Patients with HR-/HER2+ and HR-/HER2-tumors had smaller pathologic tumor sizes and a greater proportion had fewer than four positive lymph nodes identified at pathologic evaluation after surgery. The gene discussed is ERBB2; the disease is neoplasm.